PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

被引:1
|
作者
Toth, Stefan [1 ]
Olexa, Peter [1 ]
Hertelyova, Zdenka [2 ]
Stefanic, Peter [3 ]
Kopolovets, Ivan [3 ]
Berek, Peter [3 ]
Filip, Vladimir [4 ]
Chakravarty, Ryan [1 ]
Siroka, Monika [5 ]
Pella, Daniel [6 ,7 ]
机构
[1] Pavol Jozef Safarik Univ, Air Force Mil Hosp, Fac Med, Dept Gerontol & Geriatr, Murgasova 1, Kosice 04086, Slovakia
[2] Pavol Jozef Safarik Univ, Dept Expt Med, Fac Med, Trieda SNP 1, Kosice 04190, Slovakia
[3] East Slovak Inst Cardiovasc Dis, Dept Vasc Surg, Ondavska 8, Kosice 04011, Slovakia
[4] Pavol Jozef Safarik Univ, Louis Pasteur Univ Hosp, Dept Orthopaed & Traumatol Locomotory Apparat, Trieda SNP 1, Kosice 04190, Slovakia
[5] Pavol Jozef Safarik Univ, Fac Med, Dept Med & Clin Biochem, Trieda SNP 1, Kosice 04190, Slovakia
[6] Pavol Jozef Safarik Univ, Fac Med, Dept Cardiol 2, Ondavska 8, Kosice 04011, Slovakia
[7] East Slovak Inst Cardiovasc Dis, Ondavska 8, Kosice 04011, Slovakia
来源
OPEN CHEMISTRY | 2020年 / 18卷 / 01期
关键词
PCSK9; inflammation; atherosclerosis; plaque; initiation; INTIMA-MEDIA THICKNESS; PLASMA PCSK9; RISK; EVOLOCUMAB; STIFFNESS; DISEASE;
D O I
10.1515/chem-2020-0147
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to detect the concentrations of PCSK9 in various subclinical stages of atherosclerosis and to highlight its relationship with inflammation. One hundred and fifty-nine healthy patients were divided into three groups, based on the extent of atherosclerotic changes in the carotid artery: a group without identifiable atherosclerosis, cIMT(>)(75 parts per thousand) and an asymptomatic plaque group. The PCSK9 was measured by ELISA and hsCRP by the immunoturbidimetric method. Vascular changes were identified by a carotid ultrasound. PCSK9 was elevated, when comparing the healthy group with the cIMT(>75 parts per thousand) group; however, no significant increase was detected between cIMT(>75 parts per thousand) and the asymptomatic plaque group. A positive linear correlation of the PCSK9 concentration and atherosclerotic changes was found; however, after the re-analysis in each group, this correlation persisted only in the group with still normal values. Additionally, a significant linear correlation was found between the PCSK9 concentrations and lipid parameters. However, no significant association was found with hsCRP. PCSK9 was found to be elevated only in cIMT(>75 parts per thousand), but not in the later plaque stage. A linear correlation of PCSK9 values was detected only in the group with still reference values. Based on this fact, we assumed the direct linear role of PCSK9 in initiating atherosclerosis; however, in the later phases, the relationship, which highlights other risk factors such as inflammation, is not linear.
引用
收藏
页码:1011 / 1019
页数:9
相关论文
共 50 条
  • [41] PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
    Lee, Jounghyun H.
    Shores, Kevin L.
    Breithaupt, Jason J.
    Lee, Caleb S.
    Fodera, Daniella M.
    Kwon, Jennifer B.
    Ettyreddy, Adarsh R.
    Myers, Kristin M.
    Evison, Benny J.
    Suchowerska, Alexandra K.
    Gersbach, Charles A.
    Leong, Kam W.
    Truskey, George A.
    APL BIOENGINEERING, 2023, 7 (04)
  • [42] PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
    Arida, Aikaterini
    Legaki, Aigli-Ioanna
    Kravvariti, Evrydiki
    Protogerou, Athanasios
    Sfikakis, Petros P.
    Chatzigeorgiou, Antonios
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [43] Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
    Xie, Wuxiang
    Liu, Jing
    Wang, Wei
    Wang, Miao
    Qi, Yue
    Zhao, Fan
    Sun, Jiayi
    Liu, Jun
    Li, Yan
    Zhao, Dong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 215 : 293 - 298
  • [44] CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis
    Gu, Bin
    Li, Min
    Li, Dan
    Huang, Kaisen
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2025, : 424 - 441
  • [45] PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
    Cheng, Jin M.
    Oemrawsingh, Rohit M.
    Garcia-Garcia, Hector M.
    Boersma, Eric
    van Geuns, Robert-Jan
    Serruys, Patrick W.
    Kardys, Isabella
    Akkerhuis, K. Martijn
    ATHEROSCLEROSIS, 2016, 248 : 117 - 122
  • [46] Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjogren's Syndrome
    Bianconi, Vanessa
    Cafaro, Giacomo
    Mannarino, Massimo Raffaele
    Perricone, Carlo
    Cosentini, Elena
    Bistoni, Onelia
    Paltriccia, Rita
    Lombardini, Rita
    Gerli, Roberto
    Pirro, Matteo
    Bartoloni, Elena
    BIOMOLECULES, 2023, 13 (09)
  • [47] Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice
    Yan, Li
    Jia, Qingling
    Cao, Hui
    Chen, Chuan
    Xing, Sanli
    Huang, Yan
    Shen, Dingzhu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [48] Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
    Caselli, Chiara
    Del Turco, Serena
    Ragusa, Rosetta
    Lorenzoni, Valentina
    De Graaf, Michiel
    Basta, Giuseppina
    Scholte, Arthur
    De Caterina, Raffaele
    Neglia, Danilo
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
  • [49] PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship
    Femino, Raimondo
    Femino, Giovanni
    Cavezzi, Attilio
    Troiani, Emidio
    INTERNATIONAL ANGIOLOGY, 2021, 40 (03) : 248 - 260
  • [50] Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation
    Lunar, Patricija
    Meglic, Hana
    Vehar, Mateja
    Ugovsek, Sabina
    Likozar, Andreja Rehberger
    Sebestjen, Miran
    Zupan, Janja
    BIOMEDICINES, 2025, 13 (02)